Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Franco-American deal gets to the point

Stephen Evans-Freke, Craig Venter, G. Steven Burrill and David Kingsbury, all household names in biotech, believe that the planned merger of ValiGene SA and Kimeragen Inc. will create - in their view - the only company capable of rapidly and inexpensively validating gene targets for drug discovery.

ValiGene (Paris, France) and Kimeragen (Newtown, Penn.) were putting the finishing touches to the merger over the weekend. The combined group will create a transatlantic functional genomics company, ValiGen N.V. (Rotterdam, the Netherlands), which will identify and validate targets for both pharmaceutical and agrochemical products. The new company also is expected to announce a private financing of $15-$20

Read the full 1049 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE